Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA^® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

01/13/20	Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States Agreement Includes an Option for Rituxan® Biosimilar REDWOOD CITY, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics , (Suzhou) Co., Ltd.,
01/03/20	Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. PT , being held in San Francisco .
11/12/19	Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences REDWOOD CITY, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Jefferies 2019 London Healthcare
11/08/19	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 7, 2019 , the compensation committee of the Company’s board of directors granted options to purchase 77,000 shares of the common

View All